[{"id":"4465b15f-e650-40db-95ec-d8d83a386576","acronym":"","url":"https://clinicaltrials.gov/study/NCT05344976","created_at":"2022-04-25T21:58:14.342Z","updated_at":"2024-07-02T16:36:11.525Z","phase":"Phase 1","brief_title":"MSLN STAR-T Cells in the Treatment of Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05344976","lead_sponsor":"Peking University","biomarkers":" EGFR • ALK • MET • ROS1 • MSLN","pipe":" | ","alterations":" ALK positive • EGFR positive • EGFR negative • MSLN positive","tags":["EGFR • ALK • MET • ROS1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • EGFR positive • EGFR negative • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YTS105"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 04/14/2022","start_date":" 04/14/2022","primary_txt":" Primary completion: 10/14/2024","primary_completion_date":" 10/14/2024","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2022-04-25"}]